Details of the Drug Combination

General Information of Drug Combination (ID: DC89Z0H)

Drug Combination Name
Tenofovir disoproxil Maraviroc
Indication
Disease Entry Status REF
HIV Infection Phase 1 [1]
Component Drugs Tenofovir disoproxil   DM62IPN Maraviroc   DMTL94F
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Tenofovir disoproxil Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [3]
------------------------------------------------------------------------------------
Tenofovir disoproxil Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [4]
------------------------------------------------------------------------------------
Indication(s) of Maraviroc
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [2]
Chronic obstructive pulmonary disease CA22 Phase 3 [2]
Maraviroc Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
C-C chemokine receptor type 5 (CCR5) TT2CEJG CCR5_HUMAN Antagonist [5]
CCR5 messenger RNA (CCR5 mRNA) TTJIH8Q CCR5_HUMAN Antagonist [6]
------------------------------------------------------------------------------------
Maraviroc Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
HIV-1-infection DCJJLVE N. A. Phase 4 [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01505114) Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 806).
3 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
4 FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
5 Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
6 Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72.
7 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
8 ClinicalTrials.gov (NCT04965662) The Role of Home Packs of HIV PEPSE in High Risk Individuals